AAL-993
CAS No. 269390-77-4
AAL-993 ( —— )
产品货号. M27434 CAS No. 269390-77-4
AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥721 | 有现货 |
|
10MG | ¥1199 | 有现货 |
|
25MG | ¥2341 | 有现货 |
|
50MG | ¥3686 | 有现货 |
|
100MG | ¥5443 | 有现货 |
|
500MG | ¥11583 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AAL-993
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.
-
产品描述AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. AAL993 has a weak inhibitory effect on other tyrosine kinases. AAL993 also shows potent antiangiogenic and antitumor activities.(In Vitro):AAL993 suppressed HIF-1α expression through the inhibition of ERK without affecting Akt phosphorylation.(In Vivo):AAL993 (24-100 mg/kg; p.o.) inhibited both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases in B16 melanoma xenograft model. AAL993 potently inhibited VEGF-induced angiogenesis with an ED50 value of 7 mg/kg in an implant model.
-
同义词——
-
通路Angiogenesis
-
靶点VEGFR
-
受体ROS;Beta Amyloid
-
研究领域——
-
适应症——
化学信息
-
CAS Number269390-77-4
-
分子量371.4
-
分子式C20H16F3N3O
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESFC(F)(F)c1cccc(NC(=O)c2ccccc2NCc2ccncc2)c1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Gül?in I, et al. Antioxidant activity of saponins isolated from ivy: alpha-hederin, hederasaponin-C, hederacolchiside-E and hederacolchiside-F. Planta Med. 2004 Jun;70(6):561-3.
产品手册
关联产品
-
Ranibizumab
Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.
-
Fruquintinib
A potent and highly selective small molecule inhibitor of VEGFR1/2/3 with IC50 of 33/3/5/0.5 nM, respectively.
-
Lenvatinib mesylate
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.